Relapsed or Metastatic

Treatment

Squamous Cell Carcinoma of Head and Neck

Lesions amenable to injection No curative Tx option

Prior Cetuximab

ENT0071
Phase I ABBV-368 (Single Agent & Combination in Locally Advanced or Metastatic Solid Tumors)

PI: Colevas Abbvie

ENT0052
Phase Ib/Ii
PIH2201
And Cetuximab in recurrent or metastatic SCC of head and neck

PI: Colevas Innate Pharma SA

ENT0068
Phase I Novel Small Molecule EBNA1 Inhibitor VK-2019 in Epstein-Barr Virus Pos Nasopharyngeal Cancer

PI: Colevas Atara Biotherapeutics

Naso-pharyngeal Carcinoma

Prior Immuno therapy

ENT0069
Phase 1B/2 Tablecleucel +/- Pembrolizumab in Recurrent Metastatic EBV in Nasopharyngeal Carcinoma

PI: Colevas Cullman Apollo Corp

Skin

Recurrent Metastatic

Pre-surgical

VAR0202
Phase II Cemiplimab alone and in Combo w/ RP1 in Advanced Cutaneous Squamous Cell Carcinoma

PI: Colevas Pending

VAR0194
Phase II Neoadjuvant Cemiplimab for Stage II to IV (Mo) Cutaneous Squamous Cell Carcinoma (CSCC)

PI: Divi Pending

KEY

Pending

Open for Enrollment

Observational Study

Optional Path

Link

Trial Posting

Extension Study

Immunotherapy

Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu